In this study, we innovatively combined scRNA-seq and bulk RNA-seq analyses to systematically resolve the heterogeneity of FGFBP2+ NK cells in HCC and its association with prognosis, and constructed a RiskScore model based on FGFBP2+ NK cell-related genes, which provides a new molecular basis for prognostic assessment of HCC patients and immunotherapy response prediction. This evidence concerns the gene FGFBP2 and hepatocellular carcinoma.